Navigation Links
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin's Lymphoma at
Date:12/7/2012

NEW YORK, Dec. 7, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that two studies featuring SL-401 updated clinical trial results in acute myeloid leukemia (AML) and other hematologic malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), and SL-101 preclinical activity against Hodgkin's lymphoma have been selected for presentation at the upcoming 54th Annual Meeting of the American Society of Hematology (ASH) to be held in Atlanta, GA from December 8-11, 2012. Stemline and its collaborators from MD Anderson Cancer Center and Scott and White Memorial Hospital will present the posters.

The updated clinical trial results for SL-401, a novel biologic targeted therapy directed to the interleukin-3 receptor (IL-3R), demonstrated that the drug was well-tolerated at clinically active doses and showed single agent anti-tumor activity in heavily pretreated patients with AML, as well as in patients with high risk myelodysplastic syndrome (MDS) and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). In particular, a single cycle of SL-401 demonstrated single agent activity in patients with relapsed or refractory AML, including two durable complete responses (CRs) of eight and >25 months duration, respectively, and multiple additional cases of leukemia blast reductions. An overall survival (OS) benefit was also notable among patients treated with only one cycle of SL-401 who were >/-3rd-line therapy for AML (n=35); the median OS was 3.6 months (95% CI: 2.3, 6.1 months), which is more than double the historical median OS results of 1.5 months for third-line AML patients treated with standard of care. Moreover, at therapeutically relevant doses defined as the MTD (16.6 µg/kg/day) or one or two dose levels below the MTD (9.4 or 12.5 µg/kg/day), the median OS among patients treated with only one cycle of SL-401 who were >/-3rd-line for AML (n = 16) was 5.6 months (95% CI: 2.5
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. ISPE Announces 2012 Award Winners at Global Annual Meeting
8. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
9. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
10. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
11. Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Companys Commercialization Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 CIO Review ( http://www.cioreview.com ... 20 Most Promising Pharma and Life Science Technology Solution ... global compliance software platform for life sciences companies. ... a panel of experts and members of CIO Review’s ... MediSpend Platform has been on our radar for some ...
(Date:4/17/2015)... 17, 2015  Guggenheim Securities, the investment banking and ... hiring of William Tanner as a Managing ... Tanner will start work at Guggenheim in May 2015 ... office. "Bill brings a wealth of biotech ... experienced and highly acclaimed healthcare team," said Matthew ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/17/2015)... BellBrook Labs announced today that they ... powerful Orthogonal Pooled Screening (OPS) Platform developed and ... Lankenau Institute for Medical Research (LCGC) in Wynnewood, ... successful drug discovery outcomes using far more efficient ... available nowhere else, coupled to a state-of-the-art compound ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... Pa., Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) ... the outstanding shares,of Apollo Light Systems, Inc., a ... light therapy systems for melatonin suppression and,circadian rhythm ... company is located in American Fork, Utah and ...
... Oct. 2 Monitorforhire.com, the,fastest source for ... even faster. The company has added a ... respond immediately to work requests via,PDA or ... Scott Freedman, president of monitorforhire.com says that ...
... Oct. 2 454 Life Sciences, a Roche,company, ... to,conduct large scale genetic re-sequencing in hundreds of ... responses to a widely,prescribed class of drug. The ... sufficient genetic variation can be identified and,validated to ...
Cached Biology Technology:Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... March 17, 2015 MedNet Solutions ... in clinical study management systems, is pleased to ... at ARENA,s Outsourcing in Clinical Trials Southeast conference ... provides an excellent forum for MedNet to showcase ... affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Spanish . Innovative, kid-friendly strategies ... skillsare emerging from scientific studies funded by the Agricultural ... Johnston, John P. Foreyt and Chermaine Tyler and their ... in which many of their Texas middle-school participants achieved ...
... in the 1990s the hole in Earth,s protective ... acid rain worse, scientists are reporting. Their study ... once used in aerosol spray cans, air conditioners, refrigerators, ... Physical Chemistry A , a weekly publication. Jeffrey ...
... Scientists at L,Oral, in hot pursuit of the hidden elements of ... "beauty is only skin deep." In fact, their work indicates that ... is much deeper. It actually is linked to molecules within the ... (C&EN), ACS, weekly newsmagazine. C&EN Senior Editor Lisa M. ...
Cached Biology News:Kids lose pounds, gain fitness in Houston study 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
...
... P Set from different Cynomolgus monkey ... organs maybe available upon request. ... from the whole set, and pay ... All Dr. P Set products ...
Biology Products: